Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic Control.
Anna C. Renner, Robert B. Kargbo
ACS Medicinal Chemistry Letters November 10, 2025 DOI: 10.1021/acsmedchemlett.5c00661 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Serotonin |
| Key findings | Patents describe psychedelic analogs optimized for 5-HT2A receptor modulation with reduced adverse effects and tunable duration of action. |
Abstract
High Resolution Image Download MS PowerPoint Slide Recent patents unveil a new wave of psychedelic analogs optimized for 5-HT 2 A receptor modulation, reduced adverse effects, and tunable duration of action. By refining DMT and psilocin scaffolds through prodrug design, fluorination, and structure–activity exploration, these innovations promise safer, shorter-acting psychedelic medicines that align with clinical workflow and improve therapeutic predictability for psychiatric disorders.
Comparable studies
Other narrative reviews on serotonin, most cited first.
Citations in the library
Cites 6
- Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications. Brain Sciences January 25, 2025
- Pharmacokinetics of Psilocybin: A Systematic Review Pharmaceutics March 25, 2025
- Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis Clinical Pharmacokinetics 2025
- Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money Annual Review of Psychology August 2, 2024
- Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity. Neuropsychiatric Disease and Treatment 2025
and 1 more in the library